Ringing in a New Year by helping save someone’s life.
It was New Year’s Day when a large, academic medical facility needed a large dose of Factor VII within six hours to help save the life of a trauma patient. Read more
Blood Systems, Incorporated has announced that the operations of BioCARE, its plasma and biological therapeutics sales division, will be transferred to BioCARE, Inc., a separate, for-profit subsidiary of Blood Systems, effective January 1, 2017. Blood Systems will own 100 percent of BioCARE, Inc.
“While this is a big change in the way BioCARE is structured as a separate legal corporation, our day-to-day operations and our workforce will stay the same,” said Linda Matthews, President of BioCARE. “The only change we foresee in our day-to-day activity under the new structure is further opportunity for growth and expansion. Our manufacturer partners will not see any changes in the way we represent them and our customers will continue to receive the first class service they have grown accustomed to since our inception.”
Blood Systems established BioCARE as an operating division in 1980 to further its charitable mission in the area of public safety by supplying blood derivatives to its customers. About 20 years later, around the year 2000, Blood Systems saw opportunities to extend services to benefit other healthcare facilities and communities and invested staff and resources to develop its signature consignment program.
The BioCARE business model was built on three pillars: consignment programs serving acute facilities, a large field sales representation and a nationwide distribution network, resulting in revenue growth of nearly 2250% in the last 15 years.
For the past three years BioCARE has expanded into the non-acute segment of specialty distribution and has experienced extreme growth in this area as well as a result of our ability to create customer solutions. Manufactures are increasingly turning to BioCARE to develop distribution strategies to improve market access and launch new specialty products.
Blood Systems President and CEO Dan Connor said the decision was made to support the anticipated growth and strategic direction for BioCARE, which has been the fastest growing division at Blood Systems in recent years with non-acute revenue having the most growth.
Founded in 1943 as the Salt River Valley Blood Bank in Phoenix, Arizona, Blood Systems is one of the nation’s oldest and largest non-profit transfusion medicine organizations.
Manufacturer Shire has named BioCARE as the exclusive, national authorized distributor for CEPROTIN, a Protein C concentrate replacement therapy. It is indicated for the prevention and treatment of venous thrombosis and purpura fulminans for pediatric and adult patients.
Linda Matthews, president of BioCARE, said, “We appreciate Shire’s continued confidence in the many capabilities of our organization. We are excited to be an integral part of helping to treat this very rare condition."
Ceprotin is offered in single-use vials that are available in 500 IU and 1000 IU nominal strengths and is for intravenous injection after reconstitution.
For more information about the efficacy and safety of Ceprotin, visit Ceprotin.
For more information on Shire and its commitment to the patient community, visit Shire.
BioCARE announced that it has been named by Bio Products Laboratory Limited (BPL) as a distributor for Coagadex (coagulation factor X, human). Product is available for shipment.
Coagadex was approved by the U.S. Food and Drug Administration (FDA) on Oct. 20, 2015. Coagadex is the first and only FDA-approved product to treat hereditary factor X deficiency, and is the only factor X concentrate available in the U.S.
Factor X ("ten") deficiency is a rare, inherited bleeding disorder caused by inadequate levels of clotting factor X protein in the blood. Similar to hemophilia A and hemophilia B, factor X deficiency is characterized by episodes of prolonged spontaneous bleeding. As one of the rarest bleeding disorders, it affects approximately 300 to 600 patients in the U.S. The goal of treatment in patients with hereditary factor X deficiency is to replace their missing factor X without adding other clotting factors the patients do not need.
"Being selected as a distributor of Coagadex shows the trust BPL has in the excellent services BioCARE provides for its customers," said Linda Matthews, President of BioCARE." As a long-time supporter of the bleeding disorders community, we are excited to continue our partnership with BPL by distributing this ground-breaking product."
To ensure a high level of service to providers of this patient community, BioCARE staff has received specialized disease state and Coagadex product training from BPL.
For full prescribing information for Coagadex visit: www.coagadex.com.
BioCAREhas been selected by Baxter as the exclusive, national authorized distributor for OBIZUR, the only recombinant porcine sequence factor VIII replacement treatment for acquired hemophilia A (AHA). OBIZUR was approved by the FDA for the treatment of bleeding episodes in adults with AHA, a very rare and potentially life-threatening acute bleeding disorder.
Linda Matthews, president of BioCARE, said, “We appreciate Baxter’s confidence in our organization and our customer- and patient-focused approach. Our unique high-touch service model has earned BioCARE a reputation among manufacturers, hospitals, treatment centers, physicians, and patients for integrity, reliability and innovation. This is an important relationship for the treatment of AHA.”
OBIZUR is offered in single-use vials that are available in 10-vial, 5- vial and 1-vial packages and is for intravenous injection after reconstitution.
For more information about the efficacy and safety of OBIZUR, clickOBIZUR_PI
BioCARE is excited to announce that Octapharma's NUWIQ is now available.
Nuwiq is the first and only recombinant FVIII produced in human cells without chemical modification.
It is indicated in children and adults with Hemophilia A for on-demand treatment & control of bleeding disorders, perioperative management of bleeding and routine prophylaxis to reduce the frequency of bleeding episodes.
It is not indicated for the treatment of von Willebrand Disease.
To order this product, call BioCARE at 1-800-304-3064.
The USDSCSA (United States Drug Supply Chain Security Act) requires product and transaction information for all sales of prescription drug products sold by a distributor or manufacturer effective July 1, 2015.
Manufacturers and distributors are required to provide the following:
Transaction Information (name of product, strength and dosage form, NDC, container size, name and address of the seller and the purchaser)
Transaction History (paper or electronic statement that include the transaction information for each prior transaction back to the manufacturer),
Transaction Statement (paper or electronic attestation by the entity transferring ownership of the product that is authorized under the Act, received the products from an authorized party, and other DSCSA specified information).
BioCARE has partnered with a group called TraceLink to provide an easy, electronic solution for you to view and download any information you need related to BioCARE products that you have purchased. Our customers will be receiving an email soon from TraceLink asking you to create an account. This is free of charge and will allow you to access the TraceLink portal at any time to view your transaction history. For more information, visit TraceLink
If you have any questions about your account, please contact our Customer Service department at 1-800-304-3064. For additional information on the USDSCSA, please visit this website.
Blood Systems, the parent company of BioCARE, has been selected by Arizona Business Magazine and BestCompaniesAZ as one of 40 winners of the 2015 Arizona’s Most Admired Companies Awards (MAC) and is featured in the September/October issue of the magazine.
Arizona’s Most Admired Companies are selected based on performance in the following areas: Workplace Culture, Leadership Excellence, Corporate and Social Responsibility, Customer Opinion and Innovation.
“This is the most comprehensive and most prestigious corporate awards program in Arizona. It recognizes the contributions and impact these ‘most admired companies’ bring to the state,” says Denise Gredler, Founder & CEO of BestCompaniesAZ and co-founder of the MAC program.
“Every day, I am proud of and inspired by the Blood Systems team,” says Dan Connor, Blood Systems President and CEO. “I am delighted that BestCompaniesAZ chose to honor my co-workers for their commitment to the donors, patients and communities we serve and for the way they live our values of respect, integrity, teamwork and excellence.”
Blood Systems—one of the nation’s oldest and largest non-profit community blood service providers—operates community blood centers serving more than 700 hospitals in 22 states, BioCARE's biological products distribution services, a quality consulting group and the world-renowned transfusion medicine research institute, Blood Systems Research Institute and is a partner in the operation of high-volume donor testing laboratories, Creative Testing Solutions.
BioCARE is a specialty distributor based in Phoenix Arizona. BioCARE has been delivering specialty and therapeutic biological products to customers since 1982, and has the expertise and networks to allow products to be available for same day and STAT delivery.